Suppr超能文献

意大利遗传性血管性水肿患者的特征与药物利用情况:一项真实世界分析

Characteristics and Drug Utilization of Patients with Hereditary Angioedema in Italy, a Real-World Analysis.

作者信息

Giacomini Elisa, Leogrande Melania, Perrone Valentina, Andretta Margherita, Bacca Marcello, Chinellato Alessandro, Ciaccia Andrea, Cillo Mariarosaria, Lombardi Renato, Mancini Daniela, Pagliaro Romina, Pastorello Maurizio, Procacci Cataldo, Degli Esposti Luca

机构信息

CliCon S.r.l. Società Benefit, Health Economics and Outcomes Research, 40137 Bologna, Italy.

Unità Operativa Complessa Assistenza Farmaceutica Territoriale, Azienda ULSS 8 Berica, 36100 Vicenza, Italy.

出版信息

Healthcare (Basel). 2023 Sep 10;11(18):2509. doi: 10.3390/healthcare11182509.

Abstract

This real-world analysis investigated the characteristics and treatment patterns of patients with hereditary angioedema (HAE) in Italy using the administrative data of health units across Italy. Patients were identified via exemption code or HAE-specific treatments (thus, all known forms, type I, II and, III, were included). The index date was that of first prescription of HAE treatments within the inclusion period (01/2010-06/2021) or of the date of exemption. The number of HAE patients included was 148 (43.2% male, mean age 43.3 years). Gastrointestinal disorders affected 36.5% patients, hypertension affected 28.4%, hypercholesterolemia affected 11.5%, and depression affected 9.5%. The frequent gastrointestinal involvement was further confirmed by the use of antiemetics and systemic antihistamines that doubled after the index date. Among patients enrolled by treatment ( = 125), = 105 (84%) were receiving a treatment for acute attacks. This analysis provided insights into the characterization of patients with HAE and their management in Italian clinical practice, suggesting that an unmet therapeutic need could be present for such patients in terms of the clinical burden.

摘要

这项真实世界分析利用意大利各地卫生单位的管理数据,对意大利遗传性血管性水肿(HAE)患者的特征和治疗模式进行了调查。通过豁免代码或HAE特异性治疗来识别患者(因此,纳入了所有已知类型,即I型、II型和III型)。索引日期为纳入期(2010年1月 - 2021年6月)内首次开具HAE治疗处方的日期或豁免日期。纳入的HAE患者有148例(男性占43.2%,平均年龄43.3岁)。胃肠道疾病影响了36.5%的患者,高血压影响了28.4%,高胆固醇血症影响了11.5%,抑郁症影响了9.5%。使用止吐药和全身性抗组胺药的情况在索引日期后翻倍,进一步证实了胃肠道受累频繁。在通过治疗纳入的患者中(n = 125),n = 105(84%)正在接受急性发作的治疗。该分析为意大利临床实践中HAE患者的特征及管理提供了见解,表明就临床负担而言,此类患者可能存在未满足的治疗需求。

相似文献

1
Characteristics and Drug Utilization of Patients with Hereditary Angioedema in Italy, a Real-World Analysis.
Healthcare (Basel). 2023 Sep 10;11(18):2509. doi: 10.3390/healthcare11182509.
3
Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor.
World Allergy Organ J. 2022 Jan 27;15(1):100621. doi: 10.1016/j.waojou.2021.100621. eCollection 2022 Jan.
5
Real-world cohort study of adult and pediatric patients treated for hereditary angioedema in the United States.
Allergy Asthma Proc. 2020 May 1;41(3):172-182. doi: 10.2500/aap.2020.41.200011. Epub 2020 Mar 18.
6
Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.
J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2379-2383. doi: 10.1016/j.jaip.2020.02.043. Epub 2020 Mar 17.
7
Real-world experience of hereditary angioedema (HAE) in Mexico: A mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns.
World Allergy Organ J. 2023 Sep 13;16(9):100812. doi: 10.1016/j.waojou.2023.100812. eCollection 2023 Sep.
8
Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights.
Drug Healthc Patient Saf. 2022 Dec 22;14:195-210. doi: 10.2147/DHPS.S345443. eCollection 2022.
9
Hereditary angioedema: a brief review of new developments.
Curr Med Res Opin. 2014 May;30(5):923-30. doi: 10.1185/03007995.2013.879441. Epub 2014 Jan 24.
10
Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII).
Allergy. 2017 Feb;72(2):320-324. doi: 10.1111/all.13076. Epub 2016 Dec 1.

引用本文的文献

1
Unmet needs in hereditary angioedema: an international survey of physicians.
Orphanet J Rare Dis. 2025 Jul 28;20(1):383. doi: 10.1186/s13023-025-03739-8.
3
Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema.
J Comp Eff Res. 2024 May;13(5):e240041. doi: 10.57264/cer-2024-0041. Epub 2024 Apr 12.

本文引用的文献

1
Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology.
Adv Ther. 2023 Mar;40(3):814-827. doi: 10.1007/s12325-022-02401-0. Epub 2023 Jan 7.
3
Comorbidities in hereditary angioedema-A population-based cohort study.
Clin Transl Allergy. 2022 Mar;12(3):e12135. doi: 10.1002/clt2.12135.
4
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.
Allergy. 2022 Jul;77(7):1961-1990. doi: 10.1111/all.15214. Epub 2022 Feb 3.
5
Impact of comorbidities on risk of angioedema without urticaria in elderly patients.
Allergy Asthma Clin Immunol. 2021 Dec 14;17(1):133. doi: 10.1186/s13223-021-00637-z.
6
Angioedema Due to Acquired Deficiency of C1-Inhibitor: A Cohort Study in Spain and a Comparison With Other Series.
J Allergy Clin Immunol Pract. 2022 Apr;10(4):1020-1028. doi: 10.1016/j.jaip.2021.11.018. Epub 2021 Nov 26.
7
Tranexamic Acid for the Emergency Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.
Cureus. 2021 Sep 20;13(9):e18116. doi: 10.7759/cureus.18116. eCollection 2021 Sep.
9
Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
Allergol Int. 2021 Jan;70(1):45-54. doi: 10.1016/j.alit.2020.07.008. Epub 2020 Sep 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验